Brief report · 28 Nov 2025
Research articlePublished 2017
Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the records of 42 patients’ treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival. Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months. Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients. Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Integrative Oncology.
Brief report · 28 Nov 2025
Biomarkers Predict Integrative Oncology Treatment Response
Opinion · 28 Nov 2025
Navigating Integrative Oncology Trial Design: Innovation and Ethics
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Integrative Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Alexandru Calin Grigorescu”
